Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

October 21, 2025

New York Stock Exchange US Consumer Staples Tobacco earnings 67 min

What were the key takeaways from Philip Morris International Inc.'s October 21, 2025 earnings call?

In the third quarter of 2025, Philip Morris International (PMI) reported strong financial results, with adjusted diluted earnings per share (EPS) of $2.24, reflecting a 17% year-over-year increase. Revenue grew organically by 5.9%, driven by robust performance in the smoke-free segment, which achieved over $3 billion in gross profit for the first time. PMI raised its full-year adjusted diluted EPS guidance to a range of 12% to 13.5%, indicating confidence in continued growth despite anticipated inventory adjustments in the fourth quarter.

What topics did Philip Morris International Inc. cover?

  • Smoke-Free Business Performance: PMI's smoke-free business showed exceptional growth, with a 16.6% increase in smoke-free volumes in Q3. Management noted, "We are especially pleased with the performance of our global smoke-free business, with outstanding volume growth for all 3 of our flagship brands: IQOS, ZYN and VEEV."
  • ZYN Growth and Promotions: ZYN's U.S. offtake growth accelerated to 39% in Q3, supported by a special promotional campaign. Management stated, "We are very happy with the result" of the promotion, which aimed to increase brand awareness among smokers and vapers.
  • Guidance Update: PMI raised its full-year adjusted diluted EPS forecast to the mid- to upper end of the previous range, now expecting growth of 12% to 13.5%. This revision reflects strong operating income growth and favorable tax dynamics.
  • Inventory Adjustments: Management anticipates inventory adjustments for ZYN of 20-30 million cans in Q4, which may impact short-term performance. They noted, "We could have shipment even slightly below adjusted in-market sales for the year."
  • Combustible Performance: Combustible volumes declined by 3.2% in Q3, but pricing remained strong with an increase of over 8%. Management highlighted the "continued resilience of our combustible business model" despite the volume decline.

What were Philip Morris International Inc.'s October 21, 2025 results?

  • Adjusted EPS: $2.24 (vs $1.91 est, +17% YoY)
  • Organic Revenue Growth: 5.9% (vs +6% to +8% guidance, inline)
  • Smoke-Free Gross Profit: $3 billion (first time achieved, significant milestone)
  • ZYN U.S. Offtake Growth: 39% (accelerated from previous quarters, positive momentum)
  • Combustible Volume Decline: -3.2% (better than expected, inline with guidance)
  • Full-Year Adjusted EPS Guidance: 12% to 13.5% (raised from previous guidance, positive outlook)

PMI's strong Q3 results and raised guidance reflect robust growth in its smoke-free segment, particularly ZYN. However, the anticipated inventory adjustments and increased promotional spending may create short-term volatility. Investors should monitor the execution of growth strategies and the competitive landscape as PMI continues to expand its smoke-free portfolio.

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the third quarter of 2025. You can find that release on our site, pmi.com. Definitions of the terms we use — covering what counts as smoke-free products, along with adjustments, other calculations, and reconciliations to the closest comparable U.S. GAAP measures for the non-GAAP financial measures mentioned in this presentation — appear in Exhibit 99.2 of the Form 8-K dated October 21, 2025, and also on our Investor Relations website. What we say today includes forward-looking statements and projections about future results. Please look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that might make actual results differ materially from projections or forward-looking statements. Emmanuel Babeau, our Chief Financial Officer, is here with me. Emmanuel, the floor is yours.

Emmanuel Babeau

executive
#2

Thanks, James, and hello to everyone joining. After a great first half, Q3 brought us really strong results. We're particularly happy with how our global smoke-free business performed, with exceptional volume increases across all 3 of our flagship brands: IQOS, ZYN and VEEV, which collectively grew faster than the global smoke-free industry by a notable amount on a year-to-date IMS basis. Sustained double-digit smoke-free revenue growth along with additional scale and cost advantages allowed us to reach over $3 billion in quarterly smoke-free gross profit for the first time ever, plus an adjusted group operating income margin exceeding 43%, the best in nearly 4 years. That powered a rise of plus 17% in adjusted diluted earnings per share, hitting a record $2.24. We achieved these impressive results even in a quarter featuring elevated commercial spending as we put money into the future growth of our brands. Our growth investments cover geographic expansion, and our smoke-free products have now been commercialized in 100 markets, among them the launch of IQOS in Taiwan this month; we're increasingly rolling out our multicategory strategy to boost growth, with all smoke-free brands now commercialized together across 25 markets. IQOS turned in excellent performance, including a very strong gross margin contribution, with Q3 HTU adjusted in-market sales growth of plus 9% against a tough prior year comparison, and plus 15.5% heated tobacco unit shipment growth. This mirrors ongoing strong momentum across Europe, Japan and global markets. The relaunch of ZYN's commercial activities drove a significant Q3 acceleration in U.S. offtake growth to plus 39%, as estimated by Nielsen. Increased marketing and promotional intensity helped lift trial among legal-age nicotine users, with encouraging repurchase intent. Fueled by the strong performance in the rapidly expanding nicotine pouch category, U.S. shipments rose by plus 37% to 205 million cans, surpassing expectations. International can volumes climbed by plus 27%, or by over plus 100% when excluding Nordic country. In e-vapor, robust VEEV momentum meant total shipments more than doubled on a year-to-date basis. VEEV now ranks as the #1 closed pod brand in 8 markets, with especially strong showings in Germany, Romania and Greece. Combustibles posted a solid Q3 with better-than-expected volumes in both Turkey and Egypt, which combined with continued strong pricing to produce a robust top and bottom line performance. Our Q3 results demonstrate our standing as the global category leader, with the capacity to generate strong growth and prioritize resources to invest heavily in our leading brands. The growing overall profitability of our smoke-free business, together with cost efficiency measures and combustible resilience, keeps us well on track for another year of double-digit adjusted operating income and earnings per share growth in currency-neutral terms, and even stronger dollar growth at prevailing exchange rates. Now to the headline financials for Q3. Positive shipment volumes, a strong smoke-free category mix and pricing produced organic top line growth of plus 5.9%, or roughly plus 7.3% when excluding the Indonesia technical impact explained earlier this year, landing within the high end of our plus 6% to plus 8% midterm growth algorithm. On an adjusted basis, operating income rose 7.5% organically and 12.4% in dollar terms, reaching $4.7 billion. Better profitability in both smoke-free and combustible products allowed us to achieve solid adjusted OI margin expansion of 120 basis points. Adjusted diluted EPS came in at $2.24, reflecting adjusted net income of $3.5 billion, which represents growth of 17.3%. That figure includes a currency tailwind of $0.08, and within that there is roughly $0.03 of favorable transactional impact during the quarter. This stronger-than-anticipated result speaks to the power of our financial model, as IQOS and ZYN both landed at the upper end of what we had expected, with additional support coming from the durability of combustibles and a more advantageous tax rate. On a year-to-date basis, our progress has been exceptional, delivering comparable growth above our midterm targets across every metric. Organic net revenue growth of 7.5%, or roughly 9% when you exclude the Indonesia technical impact, came from the same drivers as the quarter. Adjusted operating income climbed 12.5% organically and nearly 14% in dollar terms, hitting $12.7 billion, which made possible EPS growth of 16%, whether or not you include currency effects. Our year-to-date adjusted effective tax rate came in 1% below our forecast of approximately a 22% rate for the full year, and we expect a higher rate in Q4. Now to shipment volumes, where we once again posted positive growth of 0.7% in Q3, or 1.8% year-to-date. The 16.6% volume growth in smoke-free for Q3 was driven by the solid fundamentals of IQOS, with HTU shipments up 15.5% to 41 billion units — surpassing our earlier expectation even after stripping out a shipment timing benefit of about 1 billion units. Year-to-date, HTU shipments rose 12%. The outstanding volume trajectory of both ZYN and VEEV once again contributed positively to smoke-free product growth in Q3 and year-to-date, most notably including U.S. ZYN. Cigarette volumes fell 3.2% in Q3, near the better end of our 3% to 4% forecast decline for H2, and this reflected stronger-than-expected dynamics in Turkey and Egypt. Let me go deeper into Q3 net revenues. Growth of 7.3%, once you exclude the technical Indonesia impact, reflects the robust smoke-free performance I described, together with solid pricing. Total pricing added 3.1 points, with combustible pricing above 8% and a positive IQOS HTU variance partially offset by the effect of ZYN relaunch promotion in the U.S. The favorable mix impact from smoke-free growth contributed another 4.7 points. Combustible geographic mix and other factors had an unfavorable impact of 1.2 points. Currency and Scope effect contributed positively at 3.5 points. The same dynamic produced strong year-to-date top line growth, as our 3 pillars of growth — volumes, pricing, and mix — keep delivering sustainably. Looking at Q3 performance by category, both smoke-free and combustibles achieved strong gross margin expansion. Q3 smoke-free net revenues grew organically by 13.9% and gross profit by 14.8%, including the short-term impact of heightened U.S. promotions. In Q3, our gross margin went up 60 basis points, reaching 70%, which beat combustible by 3.5 points given the mix we currently have across categories and geographies. IQOS drove this result, as strong shipment volumes, pricing leverage, and cost savings together more than offset the dilution from more device sales during the quarter. Even though combustible volumes fell 3%, the business turned in another robust quarter, posting organic net revenue growth of 1%, or about 3% once you strip out the technical effect in Indonesia, while gross profit climbed a solid 4.8%. That outcome showcased how our combustible business model keeps proving resilient, since a modest single-digit volume decrease, combined with solid pricing and efficiency, keeps lifting both the top line and gross profit as time goes on. We remain firmly on course to hit our goal of organic combustible gross margin expansion, in dollar terms as well, for this year. Thanks to ongoing smoke-free momentum paired with combustible resilience, overall gross margin rose 170 basis points, hitting 67.9%, which stands as a quarterly record since the 2021 pandemic recovery. Our results so far this year have been excellent, with the favorable effect of smoke-free growth plainly visible. Smoke-free gross margin rose 360 basis points, with IQOS once more making a major contribution, alongside ZYN's superior U.S.

Emmanuel Babeau

executive
#3

Thanks to margin gains and VEEV's expanding role, along with solid combustible results, total PMI achieved gross margin growth of 260 basis points. Now looking further down the income statement at OI margin: organic expansion came in at 60 basis points during Q3, which equals 120 basis points in dollar terms, reaching a strong 43.1%. That figure captures the 170 basis point gross margin improvement I mentioned earlier, though it was partially offset by higher SG&A expenses, something we signaled three months ago. Within that is a sizable, deliberate commercial push in markets outside the U.S. aimed at growing IQOS, ZYN, and VEEV's footprint and brand value. It also covers increased marketing and brand spending for ZYN across America, now that supply is fully restored, plus additional funding for our U.S. infrastructure to enable ZYN and IQOS to grow going forward. For the full year, excluding currency effects, we expect SG&A expenses to rise somewhat faster than underlying net revenue, given this robust level of reinvestment. Continued cost discipline across both cost of goods sold and SG&A helps counterbalance these larger investments, and we stay firmly on schedule to hit our target of $2 billion in savings across 2024 through 2026. Let me turn to our worldwide smoke-free operations: across the 100 markets where we compete, the portfolio is growing faster than the category, with estimated IMS volume growth above 12% year-to-date versus under 10% for the industry overall. We put our volume share of smoke-free products in these markets at roughly 60%, while our year-to-date portion of category growth exceeds that by more than 10 points. Given our lineup of top-tier premium brands, our value-based share of smoke-free is clearly above that 60% figure. Having a multicategory portfolio is a major advantage, since we use IQOS's equity and distribution to bring more adult nicotine consumers into the category. Last year IQOS brought in over $11 billion in net revenue, and its share of the expanding worldwide heated tobacco segment sits above 75% and has held steady even as competition heats up. ZYN, though much smaller by comparison, is expanding far quicker than the category, helped by our leading U.S. position and fast momentum internationally, all backed by a portfolio built for differentiation over the long haul. The same pattern holds in e-vapor, where VEEV's brand loyalty and repeat purchasing are driving faster growth. IQOS had a solid Q3, posting 9% adjusted IMS growth against a tough year-ago figure, bringing year-to-date growth to 10%. As we noted three months ago, we're looking for double-digit growth in H2 and 10% to 12% growth in adjusted IMS for the full year, with a pickup during Q4. Continuous device and consumable innovation underpins this, with heavy emphasis on brand engagement — one illustration being the limited edition Seletti device launch in Japan, which will be followed by additional markets under our Curious X campaign. Now on to ZYN: global can shipments rose 36%, and the brand is now available in 47 markets. The third quarter includes the launch in Spain, plus a small-scale pilot rollout in Japan for ZYN by IQOS, which leverages the strong brand equity and commercial footprint of the leading smoke-free brand globally. Within the United States, can shipments rose 37%, with offtake accelerating notably — a topic I'll return to. Beyond the U.S., can shipments were up 27%, or more than 100% if you exclude the Nordics, with fast expansion coming from the U.K., Pakistan, Poland and South Africa. We keep enriching what ZYN offers, among other things through the gradual introduction of a lower strength variant within our dry-led lineup, where we're seeing repeat purchases climb substantially among legal-age smokers who are new to the oral category compared with the higher strength option. Turning to e-vapor. VEEV maintained strong momentum, and the brand now ranks #1 in closed pod across 8 markets. We posted outstanding Q3 volume growth of 91%, even with an unfavorable regulatory change in Poland. Solid volume momentum year-to-date, helped by a better pods-to-kit ratio from repeat purchasing, produced greater operating leverage and scale benefits, lifting profitability. Now looking at geography: Europe stands as the most developed multicategory region, and markets like Italy, Greece, Spain and Romania all delivered excellent growth across all 3 smoke-free categories. IQOS kept up its strong growth path in Q3, with adjusted IMS rising 7.3% against a harder comparison, driven particularly by Italy and backed by innovation on new TEREA variants plus LEVIA capsules. PMI's HTU share of the combined cigarette and HTU industry climbed 1.2 points to 10.7%, with major cities including Munich, Rome and Madrid all showing very strong growth; we anticipate a solid acceleration in adjusted IMS growth during Q4. Following many launches and expansions throughout the region over the last 1 to 2 years, ZYN's strong early traction persisted, with share gains across markets such as Poland, Switzerland, Greece and the U.K. In e-vapor, the consumer move toward closed pod keeps fueling growth. VEEV volumes doubled, and the brand now holds the #1 pod position across 7 European markets; in Japan, IQOS keeps expanding very robustly, with Q3 adjusted IMS growth of 6%, again, against a strong 14% in Q3 last year and 7.6% on a year-to-date basis; this mainly mirrors the category growth rate, with 12-month segment share steady at roughly 70%, despite a very significant step-up in competitive commercial investment and intensity, and, as in similar periods previously, somewhat more trial of discounted competitor product. As we noted last quarter, IQOS achieved truly exceptional growth in 2023 and 2024, particularly given that the category's size is nearing half of total nicotine offtake volume nationally, and exceeds half in 14 of the top 20 cities. The growth our business has delivered so far in '25 is essentially in line with the trend seen in the years before. In the third quarter, adjusted IQOS heated tobacco unit share rose by 1.8 points compared with a year earlier, hitting 31.7%, while we keep pushing innovation on IQOS and sow the earliest seeds of a multicategory rollout through launching ZYN in chosen channels and places. Now shifting to the U.S., which accounted for roughly 7% of our net revenues worldwide and 9% of adjusted operating income on a year-to-date basis. ZYN's volume results in Q3 stood out, speeding up to a 39% gain in growth per Nielsen — the quickest expansion over the past 5 quarters. Since this is the category expanding fastest within the planet's most valuable nicotine market once China is excluded, we're obviously putting money into ZYN and into what lies ahead for the category, where the brands still command more than 60% of volume share and two-thirds of value. Following a 31% offtake increase reported by Nielsen for July and August combined, our Q3 growth got a boost in September, reaching 58%, thanks to marketing and promotional backing ramping back up after multiple quarters limited by supply; now that ZYN's growth nearly matches the industry's, ZYN took most of the Q3 category gains in both volume and value, even with a noticeably smaller average price during the quarter. In fact, among every category in the U.S., ZYN ranked as the brand growing fastest by retail dollar value.

Emmanuel Babeau

executive
#4

When you look at the convenience channel, for both Q3 and year-to-date, based on Nielsen data, plus PMI U.S. at the manufacturer level as shown here, it's the same story. That really underscores how strong and powerful the ZYN franchise is, with our retail partners and with legal-age nicotine users alike, and it gives us a great platform to drive further growth from. As I said, we've recently put in place a significant step-up in marketing and brand-building overall, supporting ZYN at point of sale, along with brand visibility, brand equity and relative price positioning. During Q3, this leaned notably toward promotions. In the supply-constrained first half of 2025, Nielsen shows only about 20% of ZYN volumes were sold on promotion, while competitors were nearer 50%; now that we're back to full commercial activity, we expect to keep promotion at a higher level than H1, as we keep adapting our marketing mix to give the brand appropriate support and to support category growth. Naturally, we intend to keep ZYN's positioning clearly premium, as the leading premium brand; we also look forward to updating you on future commercial initiatives, one example being limited edition variants built on our authorized product range. As part of these reintensified activities, we also chose to run a special September promotion marking ZYN's return to full availability. It gave a free ZYN can to legal edge consumer purchasing other nicotine products in select location, and it was designed to target legal-age smoker and other nicotine users, aiming to boost awareness and trial. That fits with ZYN's mission of growing the nicotine pouch category in the years ahead, and we're very pleased with how it went. Most of those who took up the offer were smokers or vapers, with better brand perception and a promising level of repurchase intent. This offer made up a single-digit percentage of our Q3 shipment. Basically, all the promotional cost of activating the special free can offer, retail incentives included, was booked in net revenues during the quarter. That goes a long way to explaining the lower Americas top line even though volumes were growing. Given the accumulation of relaunch activities, this quarter saw exceptional investment, with roughly $100 million of Q3-specific investment and reduced revenues tied to restarting our commercial engine. Over the last 18 months, the U.S. nicotine pouch category has grown at more than 40%, and by volume it now makes up a high single-digit percentage of the nicotine market. We believe that in the coming years it can become one of the largest category in the U.S., where our estimate is that cigarettes account for more than 40% of the market, and e-vapor in the region of 30%. By value, ZYN is America's #1 smoke-free brand, with a franchise which is second to none. We are investing to support ZYN's momentum, both within and outside the U.S. Additionally, we're hopeful that the FDA's recently announced initiative to make the review pathway for nicotine pouches more efficient will produce a favorable result, since it ought to bring greater clarity and fairer competitive conditions. It's worth noting that, so far, the agency has granted authorization to just 20 nicotine pouch products, every one of them marketed under ZYN, and we're looking toward the TPSAC session regarding ZYN's MRTP application to take place during the first quarter of 2026. Taken together, we anticipate that ZYN will remain a significant engine of growth for PMI's net revenue as well as operating income. Although the lack of a complete commercial program during this year's first half generated an unusually high level of U.S. profitability, our expectation is that ZYN will keep producing best-in-class margins inside PMI. Over the nearer term, we still anticipate that H2 shipment volume expansion will roughly match offtake growth prior to any channel inventory movement; we foresee a reduction of 20 million to 30 million cans in inventory over the months ahead. That effect is essentially pushed back from Q3 because of robust September promotional activity. We're also still waiting on FDA authorization for IQOS ILUMA, which stands as, by a wide margin, the most successful product worldwide when it comes to moving cigarette users entirely off smoking. In the interim, we're proceeding with IQOS 3 pilots, among them the newest site in Jackson, Mississippi, while we likewise await renewal of our IQOS 3 MRTP, which follows the TPSAC meeting held earlier this month. Beyond the U.S., Japan and Europe, each of our 3 smoke-free segments is generating vigorous growth, with Q3 shipments rising by more than 23% to surpass 12 billion units. That figure encompasses ongoing strong IQOS results in South Korea, swift ZYN expansion in Pakistan and South Africa, and highly dynamic multicategory growth across Global Travel Retail and Indonesia. Additional IQOS key city offtake shares appear in the appendix. Turning to combustibles, our cigarette portfolio kept showing its resilience, led by a solid showing from Marlboro, which added +0.4 points to achieve a record share of 10.9%. International category share fell during the quarter, mostly because of Turkey in the wake of supply chain disruptions from earlier in the year; even so, our share is bouncing back nicely on a sequential basis and remained basically flat year-to-date. Q3 pricing of +8.3% landed ahead of what we'd expected, with gains coming from every region and particularly from Indonesia, Australia, Turkey and Germany. Though unfavorable geographic mix partly counteracted this, we now project full year pricing slightly above +7%, with a deceleration in Q4 as anticipated, owing to timing factors. Above all, and as discussed previously, our combustible business keeps making a very sturdy contribution, with gross profit growth approaching +5% year-to-date. That aligns completely with our aim of maximizing value over the long run while fueling expansion of our smoke-free business; this leads me to our full year outlook. We remain on course for an exceptionally strong performance, delivering yet another year of double-digit growth in adjusted operating income and adjusted diluted earnings per share. We begin with shipments, and we're still aiming for overall PMI growth of roughly plus 1%, which would mark our fifth straight year of volume gains. That includes a cigarette decrease of about 2% alongside smoke-free volume expansion of plus 12% to plus 14%. For smoke-free shipments, growth will probably fall in the lower half of that range, once we account for the possible inventory adjustment for ZYN that I mentioned, plus anticipated IQOS HTU shipments nearing 38 billion units in Q4. That Q4 HTU projection factors in somewhat reduced channel inventory and a reversal of approximately 2 billion units from timing impact, so HTU shipment growth ends up broadly aligned with our plus 10% to plus 12% adjusted IMS growth forecast for 2025 as a whole. Our organic net revenue growth forecast remains plus 6% to plus 8%, powered by positive volumes, smoke-free mix and pricing. In line with smoke-free volumes, and considering the top line effect of U.S. investment, the lower half of that range is likewise more probable. If you set aside the technical impact of Indonesia, our forecast growth would sit at or above the high end of our 3-year growth algorithm. We anticipate yet another year of double-digit organic operating income progression, and we now project plus 10% to plus 11.5% growth for the year, incorporating the same factor as net revenues. This growth should produce strong adjusted OI margin expansion, landing solidly back above 40%.

Emmanuel Babeau

executive
#5

That above-algorithm expansion, achieved during a period of heavy investment, plainly showcases how dynamic our worldwide growth framework is; we're lifting our projection for adjusted diluted earnings per share to the midpoint-to-upper portion of the currency-neutral growth band we gave before, at 12% to 13.5%, equal to 13.5% to 15.1% when stated in dollars. That figure incorporates an anticipated currency benefit of $0.10, and for 2026 we'd anticipate a benefit of comparable magnitude, assuming exchange rates stay where they are now. For the full year 2025, the outlook assumes an adjusted effective tax rate near 22%, reflecting our most recent evaluation of tax developments and market mix. Looking at Q4, we anticipate our smoke-free segment continuing to perform strongly, helped by faster growth in IQOS adjusted in-market sales. On the financial side, as anticipated, we see a softer quarter because of the moving parts I described regarding IQOS shipments and possibly ZYN, the scheduling of price increases alongside falling combustible volumes, and a heavier tax burden. Weighing those elements, along with ongoing brand spending and comparison effects, we project a quarter with slower revenue growth, organic operating income rising by a single-digit percentage, and currency-neutral adjusted diluted EPS growth of as much as 6%. Beyond that, we're raising our projection for full-year operating cash flow to above $11.5 billion, using current exchange rates and contingent on working capital needs at year-end. That mirrors robust full-year profit generation and cash conversion, and it now incorporates a Q3 dividend from our Canadian affiliate, which we have deconsolidated. Turning to our balance sheet, we keep aiming for additional deleveraging during 2025, though euro-dollar currency fluctuations could, naturally, affect where our leverage ratio lands at year-end, since our debt is euro-denominated. Crucially, we're still on course to hit a ratio of roughly 2x net debt to EBITDA by the close of 2026. Thanks to our robust performance so far this year and the full-year results we expect, we're firmly on track to surpass our 2024 to 2026 CAGR targets, which already stand as a best-in-class growth profile among consumer packaged goods companies. With that much solid progress already achieved and an attractive growth outlook ahead over the next several years, we approach 2026 and beyond with confidence. To sum up, what we've delivered so far this year shows the strength and momentum behind our worldwide smoke-free business, paired with the durability of combustibles. Our smoke-free operation keeps growing more profitable, led by IQOS and ZYN. We stay enthusiastic about our potential for future growth as we keep implementing our multicategory strategy and putting money into our premium brands that lead their categories. Strength across every category underpins our financial model, supported by proactive steps on pricing and cost savings. That fuels our assurance in delivering robust, sustainable adjusted diluted EPS growth in both currency-neutral and dollar terms. Thanks to our disciplined capital allocation approach, we can both reinvest at the right level to support and enhance our smoke-free portfolio and reward our shareholders. During September, we boosted the dividend for an 18th straight year, taking it to $5.88 per share. That represents an 8.9% increase — the biggest since 2013 — which speaks to how well we've performed so far this year and how confident we feel about where things are headed. As our transformation keeps moving forward, we're eager to keep delivering more value to shareholders. Thanks so much, and at this point we'd be delighted to take your questions.

Eric Serotta

analyst
#6

Thanks. I'd like to begin with ZYN. If I recall correctly, you mentioned before that the objective was to expand alongside the category in the near term. My assumption is that refers to volumes. Could you make that clearer? And really, since the unusually heavy promotions from September have somewhat subsided in October, we've observed that scanner data has at least softened during October, which isn't too shocking, though perhaps somewhat surprising given how large the change was. So then, how are things progressing in October relative to what was planned? And regarding the IQOS business, might you offer more detail about why HTU shipments don't match IMS? I'm aware there was a rather difficult comparison on the IMS side, near 15%. Still, further explanation would be useful regarding what's behind the excess shipping during the quarter.

Emmanuel Babeau

executive
#7

Eric, I appreciate your 2 questions; I'll begin with ZYN, and thanks, perhaps, for letting me clarify or restate a few things I've said. Certainly, ZYN leads the nicotine pouch category in the U.S., holding over 60% of volume share and 2/3 of value share. Growing the category, developing it, building awareness around it—that's our role and our mission; naturally, as the leader, we'll gain from that. As I noted in my comments, we perceive enormous potential for this category, which across recent quarters has expanded somewhere between 30% and 40%. That momentum remains. So, as expected, through our specific promotion—and I'll return to that specific promotion shortly—we've been speeding up even more, I'd say, the category's expansion. Yet the category's momentum is truly enormous; and naturally, we're quite pleased, as we mentioned, that we take the bulk of the growth, in both volume and value terms. What I'd say about this Q3 is that it can be summed up as, on one hand, a normalization that I'll describe. On the other hand, to be frank, we aimed for a sort of explosive impact since we had returned to complete availability. When the leader returns at full strength, you simply want to make that known. That involved a specific promotion on the free can. But before anything else, let me address getting back to normal. I suspect people didn't entirely grasp this, yet throughout a year of constrained ZYN availability, we were, I'd say, operating at a profitability level that was unusual, since promotional activity stayed quite minimal; we pointed out that during H1, promotional levels ran about 20% on price, whereas the remainder of the category and the category's norm sits closer to 50%. That doesn't mean we're going to 50%, it's simply to illustrate the gap. If I actually look at Q3 '24, our promotional percentage was in the single digits, so essentially no promotion at all. What's been going on in Q3 is that now, with full availability restored, we naturally want to capture our fair share of growth. We are a premium brand, and we remain one. But as Jacek pointed out a few weeks back, there was a substantial gap caused by that minimal promotional activity and the very aggressive discounting, I'd call it, from competitors. It mattered for us to move toward a more typical promotional level — definitely not to eliminate the gap, but simply to bring it down to something more acceptable on the premium side. ZYN stays and will stay a premium brand. So that's what I refer to as normalization, which took place in Q3; we're shifting to a standard level of promotional activity, which is one element — not the sole one — of the mix for growing ZYN going forward. Beyond that, there was the blast effect I've mentioned, which is way back, way back in a major way. And yes, it's accurate that we see a mission in making sure the category is known and understood, building awareness, which remains low in numerous instances. I believe we can say roughly 80% of that free can promotion reached smokers and vapers. We know future growth will come notably from converting those smokers and vapers to nicotine pouch. We were glad to do it, and we're extremely pleased with the feedback this promotion is generating. Now we recognize this comes at a cost. I've noted in my remarks that restarting this promotion and all of it — this restart of the machine pushing ZYN at the proper level, I'd say — has cost about $100 million in reduced sales. And this one, of course, is more exceptional in nature. So really 2 elements. First, we're now in a normal situation, whereas in prior quarters we weren't in a normal situation regarding net price positioning. And second, this kind of one-off, special, not necessarily repeatable promotion occurred in Q3; that explains what happened in Q3. Now you were asking, okay, what's been happening with consumer offtake? Honestly, the first 2 weeks, I think, came in above 30% or slightly under 30% for consumer offtake, and we maintain very strong growth. In fact, looking at Q3 excluding the special free can promotion, we stood at 3% — sorry, 30% plus growth. It appears we're entering the final quarter with the same momentum we saw in Q3 when it comes to how consumer offtake is developing. On your second question, which was about IQOS and the gap between shipments and IMS: yes, as of the close of September, HTU shipment growth — that is, shipment growth for IQOS consumables — sits above 12%, while our IMS growth is far nearer to 10%. So we anticipate IMS growth picking up pace during Q4; even so, we also expect to bring shipments and IMS clearly into line in Q4; and I wouldn't even rule out the chance — since, as you're aware, we adjust inventory levels in various places — of shipments landing somewhat under IMS for the full year. That's the way Q4 will play out. Naturally, this affects the financial results in Q4, yet we're extremely happy with how IQOS is performing on IMS, which truly is the driver over the long term, and in numerous markets the brand is performing exceptionally well. Thank you.

Matt Smith

analyst
#8

I'd like to build on what you said about the U.S. ZYN business, and get a clearer read on those remarks in the release about ZYN holding a margin structure that's best-in-class, or best within the group, compared with how things performed here in Q3. Regarding that $100 million of investment made during the quarter, does that level persist — or rather, is it a level of investment we should treat as normalized, one that sets up a tough comparison until this same point next year? Or should we be factoring in other things?

Emmanuel Babeau

executive
#9

Sure, Matt. Let me make this clear once more. That $100 million is one-off, all right? It covers the entire cost of this special promotion on one hand, plus relaunching the machine. So it's one-off and nonrepeatable — that's one piece. Then the other piece, like I mentioned, is that with a fresh level of promotion activity, that becomes a normal one. Again, I'm not claiming we'll match the rest of the category and the competition, which is extremely aggressive, but our promotional activity will be significantly higher compared with, as I mentioned, 20% in H1 and single digit in Q3 '24; that's what you should anticipate going forward. Still, with that in mind, I'm glad to say again that we expect ZYN, in this new normal — or in this normal situation, I'd call it — to remain very nicely the best-in-class margin in the group.

Matt Smith

analyst
#10

You mentioned that in Q4, operating profit growth was in the single digits on an underlying basis. Could you give us some more color on what's driving that? What portion comes from timing tied to inventory for IQOS and ZYN, as opposed to investment staying at elevated levels in the U.S., or other factors?

Emmanuel Babeau

executive
#11

Sure, Matt. If I were to boil the message down, it's that the business's momentum will carry on into Q4. On the smoke-free portfolio, we anticipate IQOS actually speeding up, and ZYN continuing its very rapid expansion. Naturally, we anticipate solid results in the U.S., yet it extends past the U.S., and we likewise anticipate that to keep expanding quite well. So when it comes to underlying consumer offtake growth, nothing is different. Every margin element remains identical, and nothing has shifted; so that is truly what will shape the number, and the explanation Q4 will come in below the first 9 months — which, naturally, look impressive where growth is concerned. At every level — operating income and adjusted EPS growth — it really comes down to this inventory movement, I'd say. Nothing about the momentum has shifted. On combustibles, which I'm aware still make up 50% plus of the group, we anticipate a volume decline once again in the 3% to 4% range; so our H2 view hasn't shifted at all. What will be somewhat less favorable is price increase, since we do anticipate — given phasing of pricing and similar factors — a weaker Q4; so that will hit the quarter; I won't claim it will be enormous, because we still anticipate decent price increase in Q4, but it would be somewhat less favorable than the first 9 months; beneath that, expect us to keep investing at a substantial pace behind our portfolio. The growth — the growth potential is tremendous, and we want to maximize it. Naturally, that comes with investments; and I also noted in my remarks that the tax rate will be considerably higher, landing us near 20%, which is how we see it today. So in Q4 it will be considerably higher than across the first 9 months, landing us at 22%. That too is a negative hit for Q4. But make no mistake, we don't anticipate the business's momentum changing. You have all these technical effects I've just described.

Bonnie Herzog

analyst
#12

Okay. Emmanuel, I'd like to ask about the guidance. You mentioned this already, but I suppose I was hoping to get a few points cleared up. Those increased investments in the U.S. — are they entirely tied to ZYN? Or are you also ramping up spending for IQOS or the complete scheduled launch of ILUMA? And is any part of this pulled forward from next year? Or should we anticipate that stepped-up U.S. spending will keep going next year too? Then, regarding guidance, I also want to grasp what's driving your raised full year dollar EPS growth outlook even though the operating income growth outlook came down. What's driving things below the line? And I believe I already know, but how have those elements shifted since the start of the year?

Emmanuel Babeau

executive
#13

Sure, Bonnie. So regarding the U.S. investment step-up — the U.S. is a growth market for us, I mean. Thanks for the chance to say that again. In the U.S., we have a unique opportunity. This market is basically smoke-free for us. We currently hold the top brand in the most vibrant category. And with luck, we're nearing the point where we can introduce IQOS ILUMA, a product that has been amazingly successful all around the globe. And we're certain it will prove highly attractive to the nearly 30 million smokers still in this market; so this is an extremely appealing market, and we foresee considerable growth ahead. And naturally, consistent with the potential we perceive here, we're putting substantial money into this country. We're obviously backing ZYN's potential and ZYN's growth. We keep growing the team so it's at the proper level to promote and develop this very thrilling portfolio; that clearly, you're correct, has an effect on 2025, but it's also definitely something we'll carry on with going forward. So the investments aren't halting in '25. That will, naturally, across every dimension — commercial footprint, marketing spend, but also our presence in the country when it comes to the ability to work at the state level with the right personnel. These are investments we're making step by step. And we are indeed still investing behind IQOS to get ready for the future launch. So all of that is absolutely at play in the U.S. and affecting the U.S. On the full year guidance — yes, clearly, everyone gets it — if you look at the $100 million and the revision, which is truly the new piece of this Q3 and the guidance revision, everyone sees where the guidance revision originates. May I nonetheless note that there's still a chance we end up above 11%, which was the earlier guidance? Thus, we shall observe how the fourth quarter plays out; and the reason we're increasing EPS is that, to put it plainly, we still, all the same, anticipate quite robust operating income growth; plus, as we described, our outlook on the tax rate has become somewhat positive, or better. And I ought to mention as well that interest expenses aren't moving in an adverse way, but instead in a beneficial way. Consequently, things might turn out slightly superior to our original assumptions. Yet at bottom, to put it plainly, the EPS increase — that solid double-digit figure — stems from growth in OI, all right? That's a potent motor we possess, and it's driving the business quite effectively. Well, as an extra bonus on top of that, in fact, tax appears to be heading in the proper direction.

Bonnie Herzog

analyst
#14

All right, that's useful. And maybe one short follow-up about the free can promotion in ZYN. Emmanuel, you brought it up and described it as a success. Did it truly draw new consumers to the brand? If that's the case, can you tell us what share of the free can promotion ended up being new consumers for the brand? And I'd also like to know why you decided to run that promotion in that manner instead of a BOGO. I ask because it seems — did it cause some rival brands to experience a volume lift because of your promotion and how it was carried out?

Emmanuel Babeau

executive
#15

Look, I won't get into how pertinent our commercial policy is, and frankly I believe we disclose plenty, compared with — that's something I was saying recently when speaking with investors — I read what other companies say about their own actions, and I think we share quite a lot. So on the upside, it's clear we'll probably need time before we see the complete effect. But in terms of generating awareness for the category and for the ZYN brand, the comprehension, the initial trial, we've gotten some feedback, and keep in mind we halted that promotion several weeks back, and it's been very positive. And it's clear we're bringing in new customers for ZYN. I can't yet at this point quantify it for you, but it's clear there's a favorable effect. Regarding BOGO compared with what we did, we could debate that, but let's return to what the aim of this free can initiative actually was. It was truly about making a big splash, creating a blast; we want people to have a first, let's say, connection with this category. If you do buy one, get one free, well, you're targeting your existing consumer, you aren't recruiting, you aren't building awareness among possible new customers. I mentioned that I'm very glad to restate that the potential of the nicotine pouch category is huge. This category is expanding extremely quickly. It's a category with the potential to eventually become as large as vaping, perhaps as large as combustibles. As the leader, our role, our mission is to make it known, to make it understood, and to help drive the category's growth. Do we help others, since they also sell nicotine pouches when we expand the nicotine pouch category? Yes, likely. But here's the thing, as the clear leader of the category, we're the primary beneficiary of this promotion. Again, I'm not saying we'll repeat it every quarter. I'm certain you grasped that. It was a sort of exceptional moment, but I believe we're very happy with the outcome.

Faham Baig

analyst
#16

I want to start with heated tobacco, since you noted that competition there is heating up. What I take that to mean is the two launches that happened in Japan over the last few months, both of which come with a big promotional push behind them. So the real question, as I see it, is whether these rival rollouts will play out the way they always have — barely denting how IQOS performs. Should we expect the same outcome now, with IQOS still managing to hold its high single-digit growth rate in Japan?

Emmanuel Babeau

executive
#17

Appreciate that, Faham. Obviously, this is hardly the first time we've faced competitors — they try different approaches, bring out new ideas and put more money in. Still, I should recognize that in certain segments this time around, the pressure is arguably even stronger, and honestly — this is my opening point — that's something we welcome, since for a very long stretch we stood alone in this industry conveying the impression that heat-not-burn represented a remarkable category breakthrough for smokers, one capable of genuinely converting them and capturing a major share of the smoke-free segment, and quite possibly the optimal route for converting smokers. So it appears more competitors are arriving at that view; their offerings are getting better. They're investing in innovation. Our expectation has consistently been that this represents typical market evolution, and that as rivals in the category step up, they would put more money behind it. That is indeed what we're seeing. Yet what's notable is that here in Japan, as elsewhere, our position stays remarkably steady when you look at the total share within this category. Our share is above 75%, and that's been the case for the past five or six years, which is pretty remarkable. Usually, when you introduce a new segment or innovation, the frontrunner tends to remain the frontrunner at an elevated level for a long stretch, though typically they do give up some share as competing options emerge — especially since many of those alternatives come with lower prices and aim to attract customers through cheap positioning. In our case, though, we've held steady, and Japan is certainly no different. As you can see—and I believe we've been sharing the figures—our portion of the category remains extremely steady, and that clearly speaks to how powerful IQOS is and how good our offering is, which in my view gives the consumer an experience unlike any other. So while I don't want to sound complacent, we do feel confident in our ability to stay a strong leader and keep a very strong leadership position both in Japan and elsewhere; so from our standpoint, there's definitely a vision that Japan will remain a market where we can achieve very solid growth. I won't provide any outlook at this point regarding 2026, though Japan definitely strikes me as a market that will expand down the road. To finish up the point I was making, it's genuinely heartening to see the industry putting substantially more money behind smoke-free offerings across the globe, and particularly behind heat-not-burn. And because we sit in the number one spot within that category, we see that as very good news for us.

Damian McNeela

analyst
#18

I've got 2 brief questions, if you don't mind. First, how much visibility do you actually have into that Q4 inventory adjustment you're anticipating, and how confident are you in it? Second, what would you say is a sustainable price premium over the long term for ZYN in the U.S.?

Emmanuel Babeau

executive
#19

Thanks, Damian. Starting with the inventory adjustment. Again, I believe your question covered both IQOS and ZYN. Regarding IQOS, like I mentioned, we anticipate bringing our shipments roughly in line with our in-market sales. In Q4, we're looking for in-market sales to accelerate. At the close of September we were near 10%, slightly higher; that's what will shape how much adjustment we make. On top of that, as I noted, particularly in Japan, and contingent on logistics circumstances and how matters develop, we might choose to bring inventory down somewhat further. I wouldn't call it hugely significant, but it does mean our shipments could end up marginally under adjusted in-market sales for the year. We'll find out. And during my remarks, I mentioned we anticipate an adjustment of roughly 2 billion sticks in Q4. That covers IQOS. Now for ZYN, we pointed out that with this market returning to normal, inventory held by wholesalers and distributors sat above typical levels, and we'd likely work that down over the months ahead — 20 million to 30 million cans. We had thought this would play out at the close of September. However, because promotional activity was running high, it didn't occur; so my inclination is to think it will occur in Q4, yet what September showed makes me somewhat more cautious about being certain that this adjustment will, when it finally comes, land in Q4 with 100% certainty. Still, that's what I'd expect. As for the ZYN premium, naturally, that's a highly sensitive matter. You can't expect me to put a figure on it. That said, ZYN's current growth and its price positioning certainly affirm that ZYN merits and earns — given the franchise, the brand's strength, the one-of-a-kind emotional bond with the U.S. consumer — a very attractive premium, and we plan to maintain a very attractive premium going forward. Naturally, I won't go into detail about exactly what that is.

Faham Baig

analyst
#20

Sorry, Emmanuel — I had another thing I wanted to ask. Thanks to the operator for letting me back in. So my second item concerns a possible ZYN Ultra rollout in the U.S. You mentioned during your remarks that the FDA has confirmed it intends to review nicotine pouch applications more efficiently. What I'd like to know is when you think that process might wrap up? Or would you think about bringing the product to market before getting an approval? A few of your competitors appear to be doing that; I simply wanted to check whether the product set to launch, ZYN Ultra, matches the 2021 application that covers the 6-milligram and 9-milligram strengths along with the 10 flavors.

Emmanuel Babeau

executive
#21

Well, speculating isn't something I'll do. The FDA, I believe, has been communicating about its program to speed things up and provide clarity regarding certain applications it might move faster on. So what will happen, I won't speculate about. That said, we certainly hope the FDA will create a level playing field and make sure every competitor can bring their product forward and isn't put at a disadvantage because some are on the market while others are not permitted. That's something we hope occurs as soon as possible and, of course, over the coming months. We're watching the situation. We observe what other competitors are doing. We're weighing every option; but at this stage, there's nothing further I can add. Once again, for us, the expectation that the FDA creates a level playing field is truly our ask and our priority. Commenting on the characteristics of the ZYN Ultra PMTA isn't something I think we've ever done. But certainly, these are products that would arrive with some differentiation versus the ZYN dry that today already enjoys a PMTA.

James Bushnell

executive
#22

Much appreciated. That brings today's call to a close. We're glad you could be with us. Should anything further come to mind, feel free to reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.

Emmanuel Babeau

executive
#23

Thank you. Speak to you soon.

Operator

operator
#24

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.